References
- BartonSZabagloLA’HernRAssessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancerBr J Cancer2012106111760176522531639
- GoldhirschAWoodWCCoatesASGelberRDThürlimannBSennH-JPanel membersStrategies for subtypes – dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Ann Oncol2011221736174721709140
- KimROsakiATogeTCurrent and future roles of neoadjuvant chemo therapy in operable breast cancerClin Breast Cancer20056322323416137432
- WolffACHammondMEHicksDGRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateArch Pathol Lab Med2014138224125624099077
- HammondMEHayesDFDowsettMAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerArch Pathol Lab Med2010134690792220524868
- WolffACHammondMEHicksDGRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateJ Clin Oncol201331313997401324101045
- LesterSCBoseSChenYYMembers of the Cancer Committee, College of American PathologistsProtocol for the examination of specimens from patients with invasive carcinoma of the breastArch Pathol Lab Med2009133101515153819792042
- BurgeCNChangHRAppleSKDo the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens?Breast200615216717216095904
- LorgisVAlgrosMPVillanuevaCDiscordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumourBreast20112028428721288720
- LowerEEGlassEBlauRHarmanSHER 2/neu expression in primary and metastatic breast cancerBreast Cancer Res Treat200911330130618273700
- GuarneriVGiovannelliSFicarraGComparison of HER 2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient managementOncologist20081383884418650259
- LeeSHChungMAQuddusMRSteinhoffMMCadyBThe effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancerAm J Surg2003186434835014553848
- KinsellaMDNassarASiddiquiMTCohenCEstrogen receptor (ER), progesterone receptor (PR), and HER 2 expression pre- and post-neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experienceInt J Clin Exp Pathol20125653053622949935
- van de VenSSmitVTDekkerTJNortierJWKroepJRDiscordances in ER, PR and HER 2 receptors after neoadjuvant chemotherapy in breast cancerCancer Treat Rev20113742243021177040
- YangYFLiaoYYLiLQXieSRXieYFPengNFChanges in ER, PR and HER 2 receptors status after neoadjuvant chemotherapy in breast cancerPathol Res Pract201320979780224183366
- LeeHCKoHSeolHExpression of immunohistochemical markers before and after neoadjuvant chemotherapy in breast carcinoma, and their use as predictors of responseJ Breast Cancer201316439540324454461
- BonnefoiHLitièreSPiccartMEORTC 10994/BIG 1-00 Study Investigators. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trialAnn Oncol201461128113624618153